[HTML][HTML] Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia
I Iacobucci, S Kimura, CG Mullighan - Journal of clinical medicine, 2021 - mdpi.com
Acute lymphoblastic leukemia (ALL) is the most successful paradigm of how risk-adapted
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities
TH Tran, SP Hunger - Seminars in cancer biology, 2022 - Elsevier
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and constitutes
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …
[HTML][HTML] Disease-associated AIOLOS variants lead to immune deficiency/dysregulation by haploinsufficiency and redefine AIOLOS functional domains
HS Kuehn, IS Sakovich, JE Niemela… - The Journal of …, 2024 - Am Soc Clin Investig
AIOLOS, also known as IKZF3, is a transcription factor that is highly expressed in the
lymphoid lineage and is critical for lymphocyte differentiation and development. Here, we …
lymphoid lineage and is critical for lymphocyte differentiation and development. Here, we …
[HTML][HTML] Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
Background Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML)
and their impact on clinical outcomes is controversially discussed. Methods We …
and their impact on clinical outcomes is controversially discussed. Methods We …
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by
recurrent, prognostic genetic alterations, many of which are cryptic by conventional …
recurrent, prognostic genetic alterations, many of which are cryptic by conventional …
IKAROS-associated diseases in 2020: genotypes, phenotypes, and outcomes in primary immune deficiency/inborn errors of immunity
HS Kuehn, CJ Nunes-Santos… - Journal of Clinical …, 2021 - Springer
IKAROS, encoded by IKZF1, is a zinc finger transcription factor and a critical regulator of
hematopoiesis. Mutations in IKZF1 have been implicated in immune deficiency …
hematopoiesis. Mutations in IKZF1 have been implicated in immune deficiency …
[HTML][HTML] Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
Genetic lesions of IKZF1 are frequent events and well-established markers of adverse risk in
acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on …
acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on …
Prognostic significance of IKZF1 deletions and IKZF1plus profile in children with B‐cell precursor acute lymphoblastic leukemia treated according to the ALL‐IC BFM …
The strongest predictors of outcome in pediatric B‐cell precursor acute lymphoblastic
leukemia (BCP‐ALL) are minimal residual disease (MRD) and specific molecular …
leukemia (BCP‐ALL) are minimal residual disease (MRD) and specific molecular …
[HTML][HTML] Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
Achievement of complete remission signifies a crucial milestone in the therapy of acute
myeloid leukemia (AML) while refractory disease is associated with dismal outcomes …
myeloid leukemia (AML) while refractory disease is associated with dismal outcomes …
Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20–a very high-risk subtype in B-cell acute …
B Tang, Z Cai, Z Wang, D Lin, X He, Q Li… - Bone Marrow …, 2022 - nature.com
Genetic deletions of IKZF1 (IKZF1 del) and IKZF1 del plus other mutations (IKZF1 plus) have
been identified in B-cell acute lymphoblastic leukemia (B-ALL) with a poor prognosis …
been identified in B-cell acute lymphoblastic leukemia (B-ALL) with a poor prognosis …